lidocaine 5% / Generic mfg. 
Welcome,         Profile    Billing    Logout  
 53 Diseases   10 Trials   10 Trials   361 News 


123»
  • ||||||||||  lidocaine 5% / Generic mfg.
    Trial completion date, Trial primary completion date:  Intralipid (clinicaltrials.gov) -  Dec 27, 2024   
    P4,  N=18, Recruiting, 
    Trial completion date: Oct 2025 --> Oct 2026 | Trial primary completion date: Oct 2024 --> Oct 2025
  • ||||||||||  ZTlido (lidocaine patch 1.8%) / Sorrento
    Decreased Opioid Utilization with Lidocaine Topical System 1.8% Compared to Lidocaine 5% Patch: A Retrospective Claims Analysis (Exhibit Hall) -  Jun 29, 2024 - Abstract #PAINWeek2024PAINWeek_114;    
    51.9% of LTS patients experienced either a decrease or discontinuation of opioid use in the post-prescription period compared to 45.5% of LP patients (Chi-square test, p=0.021). LTS patients had a non-significant change in pre- versus post-prescription median Morphine Milligram Equivalents (MME) (3.1% increase, Wilcoxon signed rank test, p=0.146); while LP patients experienced a significant increase in pre-versus post-prescription median MME (42.9% increase, Wilcoxon signed rank test, p< 0.001).
  • ||||||||||  ZTlido (lidocaine patch 1.8%) / Sorrento
    Decreased Cost Utilization with Lidocaine Topical System 1.8% Compared to Lidocaine 5% Patch: A Retrospective Claims Analysis (Exhibit Hall) -  Jun 29, 2024 - Abstract #PAINWeek2024PAINWeek_113;    
    The median cost of office visits per LTS patient was $2518 pre-index and $2439 post-index (-3%, p=0.003), the median cost of ER/urgent care visits per LTS patient was $1574 pre-index and $1017 post-index (-35%, p=0.663), the median cost of outpatient visits per LTS patient was $2977 pre-index and $2984 post-index (+0.2%, p=0.906 ) and the median cost of pain procedures per LTS patient was $1150 pre-index and $1155 post-index (+0.4%, p=0.107).In contrast, the median cost of office visits per LP patient was $1862 pre-index and $1898 post-index (+2%, p=0.04), the median cost of ER/urgent care visits per LP patient was $2558 pre-index and $2501 post-index (-2%, p=0.624), the median cost of outpatient visits per LP patient was $3636 pre-index and $3926 post-index (+8%, p< 0.001), and the median cost of pain procedures per LP patient was $956 pre-index and $1024 post-index (+7%, p< 0.001). Conclusions/Implications for future research and/or clinical care: The overall cost reduction observed in the LTS cohort, and the cost increase observed in the LP cohort suggests that LTS may be associated with lower costs of care compared to LP due to better pain relief as a result of the superior adhesion qualities of LTS.
  • ||||||||||  lidocaine 5% / Generic mfg.
    Trial completion date, Trial primary completion date:  Intralipid (clinicaltrials.gov) -  Mar 6, 2024   
    P4,  N=18, Recruiting, 
    Lidocaine patches provides pain relief in a substantial portion of children with ACNES. Trial completion date: Jan 2025 --> Oct 2025 | Trial primary completion date: Jan 2024 --> Oct 2024
  • ||||||||||  An Exotic Presentation: Managing Pain in a Patient with a Rare Axonal Variant of Guillain Barre Syndrome () -  Nov 16, 2023 - Abstract #AAPMR2023AAPMR_901;    
    Current literature champions the use of gabapentin and carbamazepine as opposed to opioids in the management of GBS-related pain refractory to NSAIDs or Tylenol. When managing severe and intractable pain in patients with GBS, especially in patients with sensory nerve fiber involvement, utilizing a multimodal pharmacologic approach may be more efficacious than a single agent alone.
  • ||||||||||  lidocaine 5% / Generic mfg.
    Enrollment status:  Intralipid (clinicaltrials.gov) -  Oct 31, 2023   
    P4,  N=18, Recruiting, 
    When managing severe and intractable pain in patients with GBS, especially in patients with sensory nerve fiber involvement, utilizing a multimodal pharmacologic approach may be more efficacious than a single agent alone. Enrolling by invitation --> Recruiting
  • ||||||||||  A Rare Mimicker of Ulcerative Proctitis (Exhibit Hall) -  Jul 29, 2023 - Abstract #ACG2023ACG_1290;    
    He was prescribed Nitroglycerine 0.2% compounded with Lidocaine 5% rectal cream and advised warm soaks...The patient was treated with penicillin G resulting in resolution of his symptoms...As seen in this case, MRI and colonoscopy findings of Syphilitic Proctitis are nonspecific; but it is integral to correctly differentiate it from inflammatory causes such as IBD or malignancy to ensure appropriate patient centered treatment. Figure: Colonoscopy Images
  • ||||||||||  lidocaine 5% / Generic mfg.
    Journal:  CLINICAL EFFECTS OF HYPERBARIC LIDOCAINE AND BUPIVACAINE IN SPINAL ANESTHESIA - OUR EXPERIENCE. (Pubmed Central) -  Feb 24, 2023   
    In Group I (n-98) hyperbaric lidocaine 5% was used for spinal block...The clinical occurrence of complications and side effects during spinal anesthesia is somewhat more common in spinal block with 5% lidocaine. The compared incidence of adverse perioperative clinical effects and complications after administration of hyperbaric lidocaine and bupivacaine in spinal anesthesia was not statistically significant.
  • ||||||||||  lidocaine 5% / Generic mfg.
    Trial completion date, Trial primary completion date:  Intralipid (clinicaltrials.gov) -  Dec 5, 2022   
    P4,  N=18, Enrolling by invitation, 
    The compared incidence of adverse perioperative clinical effects and complications after administration of hyperbaric lidocaine and bupivacaine in spinal anesthesia was not statistically significant. Trial completion date: Dec 2022 --> Nov 2024 | Trial primary completion date: Nov 2022 --> Nov 2023
  • ||||||||||  lidocaine 5% / Generic mfg.
    Trial primary completion date:  Intralipid (clinicaltrials.gov) -  Apr 4, 2022   
    P4,  N=18, Enrolling by invitation, 
    In conclusion, lidocaine 5% medicated plaster was successful in relieving itching and other symptoms in this case of NP. Trial primary completion date: Mar 2022 --> Nov 2022
  • ||||||||||  Journal:  Nonopioid drugs for pain. (Pubmed Central) -  Mar 3, 2022   
    Trial primary completion date: Mar 2022 --> Nov 2022 No abstract available
  • ||||||||||  lidocaine topical / Generic mfg.
    Lidocaine patch for localized neuropathic pain: a single center audit. ([VIRTUAL]) -  Oct 31, 2021 - Abstract #Euroanaesthesia2021Euroanaesthesia_757;    
    There were no serious adverse events. This retrospective study demonstrated that a topical the Versatis patch can be considered for patients with peripheral neuropathic pain.
  • ||||||||||  dexamethasone / Generic mfg., paclitaxel / Generic mfg., docetaxel / Generic mfg.
    [VIRTUAL] MUCOSITIS AND MAGISTRATIC PHARMACEUTICAL FORMULAS FOR USE IN PATIENTS IN ONCOLOGICAL PALLIATIVE CARE: LITERATURE REVIEW () -  Oct 27, 2021 - Abstract #HEMO2021HEMO_1170;    
    The terms used were “oral mucositis extemporaneous formulations”AND/OR, oral liquid AND/OR, suspension AND/OR, compounding AND/OR, mucositis therapy AND/OR, treatment of mucositis AND/OR, mucositis agent”out, to confirm the information in the national and international literature regarding stability after preparing the formulation.Results 35 formulations have been found for use in the treatment of mucositis. Benzidamine; Sodium borate, lidocaine and pink honey; Clobetasol and nystatin; Chlorhexidine, lidocaine and nystatin; Diphenhydramine, Lidocaine, Misoprostol and Triamcinolone; Hydrocortisone 1 mg/ml, tetracycline 25 mg/ml and nystatin 25,000 units/ml mouthwash; Lidocaine compound, buccal suspension; 2% viscous lidocaine gel; Misoprostol 0.0024% and lidocaine 1% mouthwash; Nystatin 100,000 units/mL and lidocaine 2% mouthwash; Tetracycline 2.5%, dexamethasone 0.1%, chlorpheniramine 0.2% and sucralfate 2% mouthwash; 1.25% tetracycline, 0.125% diphenhydramine and nystatin 20,000 units/mL mouthwash; Triamcinolone 0.1% oral adhesive gel; Triamcinolone 0.5% and lidocaine 1% oral adhesive gel; Nystatin oral suspension, sodium bicarbonate, complex B oral solution and saline solution; Lidocaine 200 mg/ml, nystatin suspension, neomycin solution 25 mg/ml, methylcellulose 1%. 1% Mepivacaine, Hydrocortisone, Gentamicin, Nystatin, Sodium Bicarbonate; Chlorhexidine, lidocaine, nystatin and water; Diphenhydramine 2.5 mg/mL, nystatin, sodium bicarbonate and water; Sucralfate 20 g, nystatin 2 million units and 1% methylcellulose; 2% lidocaine and 2.5 mg/ml diphenhydramine; Lidocaine 5% and carbemellose 2%; Diphenhydramine, misoprostol, glycerol, lidocaine, methylose, mint and water; Diphenhydramine 0.25 g, lidocaine 2 g, h aluminum hydroxide and water; Chlorhexidine 0.12%, Lidocaine 1%, Nystatin 100,000 units and water; Lidocaine, nystatin, 70% sorbitol and water. Discussion Mucositis are inflammation of the lining of the mouth, which can cause ulcerations, discomfort and severe pain. Most chemotherapy drugs can cause mucositis, and the ones that can most cause this side effect are: capecitabine, 5-FU, doxorubicin, docetaxel, paclitaxel.Conclusion Patients use these formulas prepared from pharmaceutical presentations available at the Pharmacy Service and/ or from ampoules, tablets or capsules and our experience with the preparation and administration of these extemporaneous formulations, proves that we have obtained similar Results to other national and international hospitals, whose data have been published in the medical literature.Keywords Hematology; Good drug handling practices; Off-label use; Patient safety.
  • ||||||||||  lidocaine 5% / Generic mfg.
    Trial completion date, Trial primary completion date:  Intralipid (clinicaltrials.gov) -  Oct 14, 2021   
    P4,  N=18, Enrolling by invitation, 
    Discussion Mucositis are inflammation of the lining of the mouth, which can cause ulcerations, discomfort and severe pain. Most chemotherapy drugs can cause mucositis, and the ones that can most cause this side effect are: capecitabine, 5-FU, doxorubicin, docetaxel, paclitaxel.Conclusion Patients use these formulas prepared from pharmaceutical presentations available at the Pharmacy Service and/ or from ampoules, tablets or capsules and our experience with the preparation and administration of these extemporaneous formulations, proves that we have obtained similar Results to other national and international hospitals, whose data have been published in the medical literature.Keywords Hematology; Good drug handling practices; Off-label use; Patient safety. Trial completion date: Sep 2021 --> Dec 2022 | Trial primary completion date: Sep 2021 --> Mar 2022
  • ||||||||||  ketamine / Generic mfg., gabapentin / Generic mfg.
    [VIRTUAL] Thoracic Surgery in a Patient with a History of Opioid Resistance () -  Jun 29, 2021 - Abstract #IASP2021IASP_963;    
    An entirely opioid-free anaesthetic and post-operative analgesic plan was achieved successfully in a complex patient undergoing a painful surgical procedure. We have demonstrated a suitable alternative for patients where avoidance of opioids, or their potential side-effects, is essential.
  • ||||||||||  lidocaine topical / Generic mfg.
    Trial completion:  Pharmacokinetics of Lidocaine in Healthy Adults (clinicaltrials.gov) -  Apr 9, 2021   
    P4,  N=23, Completed, 
    No abstract available Active, not recruiting --> Completed
  • ||||||||||  lidocaine topical / Generic mfg., lidocaine 5% / Generic mfg.
    Enrollment open, Trial initiation date:  EASY: Pre-emptive Topical Lidocaine 5% Plaster for Prevention of Post-craniotomy Pain (clinicaltrials.gov) -  Oct 19, 2020   
    P3,  N=180, Recruiting, 
    This review highlights several examples whereby significant cost-savings can be made through HTM of not only new drugs, but also drugs which are already available on the market. Not yet recruiting --> Recruiting | Initiation date: Jun 2020 --> Oct 2020
  • ||||||||||  lidocaine 5% / Generic mfg.
    Trial completion date, Trial primary completion date:  Intralipid (clinicaltrials.gov) -  Oct 14, 2020   
    P4,  N=18, Enrolling by invitation, 
    Not yet recruiting --> Recruiting | Initiation date: Jun 2020 --> Oct 2020 Trial completion date: Jun 2021 --> Sep 2021 | Trial primary completion date: Sep 2020 --> Sep 2021
  • ||||||||||  lidocaine topical / Generic mfg., lidocaine 5% / Generic mfg.
    Clinical, Journal:  Ice versus lidocaine 5% gel for topical anaesthesia of oral mucosa - a randomized cross-over study. (Pubmed Central) -  Sep 21, 2020   
    CONCLUSIONS : According to our model calculation the 5% lidocaine medicated plaster is cost saving as first line treatment option in PHN and a highly cost-effective for the management of patients with DPN in Colombia compared with pregabalin form the Colombian GSSHS perspective. The cheap and readily available described method using ice for topical anaesthesia of oral mucosa before dental injection is an effective alternative to lidocaine 5% gel.
  • ||||||||||  lidocaine topical / Generic mfg.
    Clinical, Review, Journal:  Topical Treatment of Localized Neuropathic Pain in the Elderly. (Pubmed Central) -  May 13, 2020   
    However, more information is needed on the efficacy and safety of lidocaine 5% and capsaicin 8% in older old persons and on the long-term effects of these pharmaceuticals. These studies should also pave the way for research and development in the field of topical analgesics with a satisfactory level of evidence-based medicine.